Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study.

Sara Bayat,Koray Tascilar,Daniela Bohr,Gerhard Krönke,David Simon,Johannes Knitza,Fabian Hartmann,Georg Schett,Arnd Kleyer

RMD open（2022）

引用 1|浏览14

暂无评分

摘要

In routine practice, BARI is effective as monotherapy in case of MTX intolerance with overall high drug persistence rates. No new safety signals were observed.

查看译文

关键词

Baricitinib,Combination treatment,Drug survival,Remission,Rheumatoid Arthritis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要